Sanofi posts 'better than expected' Q2 results, analysts say
Sanofi stock rises on licensing deal with Maze for Pompe disease drug | Seeking Alpha
Sanofi coughs up $180M to settle Pompe disease royalty payment dispute | Fierce Pharma
Live Webinar: Journey into Rare World - Everyone's role in diagnosis of Pompe disease - The Malaysian Paediatric Association
U.S. FDA approves another Sanofi drug for rare muscle disorder Pompe disease | Reuters
Sanofi-Aventis Korea expects Nexviazyme to be game-changer for Pompe disease < Pharma < Article - KBR
Nexviazyme has been applied for domestic permission
Sanofi's drugs to treat Pompe disease and Niemann-Pick disease to be available in India soon- The New Indian Express
Sanofi on LinkedIn: #pompe | 20 comments
Sanofi extends its Pompe range with first Nexviazyme OK | pharmaphorum
Sanofi Finds Way to Maze Therapeutics to Get Its Next Pompe Disease Drug - MedCity News
Pompe Disease Therapeutic Market Report 2022:2028 – Industry Growth Forecasts by Manufacturers, Countries, Type and Application | Amicus Therapeutics, Inc., Valerion Therapeutics, LLC, Sanofi S.A., Oxyrane, - Digital Journal
PPT - Pompe Disease (Sanofi Portfolio in rare diseases, Ukraine) PowerPoint Presentation - ID:9053885
Amicus's path to unseat Sanofi in rare disease gets steeper after Phase 3 miss - MedCity News
Sanofi US on X: "Have you heard of #Pompe disease? Just knowing the symptoms of this #RareDisease could help reduce the time to diagnosis. Share with the hashtag #GreaterThanPompe to raise awareness
Sanofi finds new Pompe disease therapy in Maze | pharmaphorum
Sanofi In-Licenses Pompe Disease Therapy From Privately-Held Maze Therapeutics For $150M Upfront
Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice | Journal of Pharmacology and Experimental Therapeutics
Sanofi Secures FDA Nod in Late-Onset Pompe Disease | BioSpace
Sanofi Launched Advanced Treatment for Pompe Disease | CCI France Taiwan
Sanofi pumps up its Pompe portfolio with Maze deal | Evaluate
Enzyme Replacement Therapy (ERT) – Pompe Disease (Glycogen Storage Disease 2)
Shining a Light on Diagnosis for Rare Genetic Disease Patients
FDA approves Sanofi's Nexviazyme for Pompe disease treatment
